Mathias Brügel

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Olivier Bouché · 13 shared papers, 2020–2026 · strength 2.43
   • Paper Characterisation of early-onset pancreatic adenocarcinoma molecular profile compared to average-onset pancreatic adenoc… DOI 10.1016/j.pan.2026.03.002↗
   • Paper Pesticides and risk of pancreatic adenocarcinoma in France: a nationwide spatiotemporal ecological study between 2011 a… DOI 10.1007/s10654-024-01176-8↗
   • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
2. Marine Perrier · 5 shared papers, 2023–2025 · strength 0.94
   • Paper Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic can… DOI 10.1038/s41430-025-01566-5↗
   • Paper Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and… DOI 10.1002/ueg2.12602↗
   • Paper Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pan… DOI 10.1016/j.pan.2023.03.005↗
3. Michaël Génin · 2 shared papers, 2024–2026 · strength 0.59
   • Paper Characterisation of early-onset pancreatic adenocarcinoma molecular profile compared to average-onset pancreatic adenoc… DOI 10.1016/j.pan.2026.03.002↗
   • Paper Pesticides and risk of pancreatic adenocarcinoma in France: a nationwide spatiotemporal ecological study between 2011 a… DOI 10.1007/s10654-024-01176-8↗
4. Florian Slimano · 3 shared papers, 2023–2025 · strength 0.59
   • Paper Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic can… DOI 10.1038/s41430-025-01566-5↗
   • Paper Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pan… DOI 10.1016/j.pan.2023.03.005↗
   • Paper Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective… DOI 10.3389/fphar.2023.1137791↗
5. Tullio Piardi · 4 shared papers, 2021–2024 · strength 0.56
   • Paper Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and… DOI 10.1002/ueg2.12602↗
   • Paper Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival… DOI 10.3389/fonc.2022.980659↗
   • Paper Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resecte… DOI 10.1186/s12893-021-01409-7↗
6. Camille Evrard · 3 shared papers, 2022–2025 · strength 0.51
   • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
   • Paper Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre … DOI 10.1016/j.pan.2023.06.010↗
   • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
7. Nicolas Williet · 3 shared papers, 2022–2025 · strength 0.51
   • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
   • Paper Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre … DOI 10.1016/j.pan.2023.06.010↗
   • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
8. David Tougeron · 3 shared papers, 2022–2025 · strength 0.51
   • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
   • Paper Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre … DOI 10.1016/j.pan.2023.06.010↗
   • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
9. Gaël S. Roth · 2 shared papers, 2022–2025 · strength 0.35
   • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
   • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
10. Jean‐Baptiste Oudart · 1 shared paper, 2026 · strength 0.32
    • Paper Characterisation of early-onset pancreatic adenocarcinoma molecular profile compared to average-onset pancreatic adenoc… DOI 10.1016/j.pan.2026.03.002↗
11. Anthony Turpin · 2 shared papers, 2022–2023 · strength 0.27
    • Paper Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre … DOI 10.1016/j.pan.2023.06.010↗
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
12. Stéphanie Truant · 2 shared papers, 2022–2023 · strength 0.27
    • Paper Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre … DOI 10.1016/j.pan.2023.06.010↗
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
13. Marie Müller · 1 shared paper, 2025 · strength 0.25
    • Paper Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). DOI 10.1016/j.esmogo.2025.100142↗
14. Éric François · 1 shared paper, 2025 · strength 0.22
    • Paper Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic can… DOI 10.1038/s41430-025-01566-5↗
15. Cindy Neuzillet · 2 shared papers, 2020–2021 · strength 0.21
    • Paper Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resecte… DOI 10.1186/s12893-021-01409-7↗
    • Paper Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic ade… DOI 10.1016/j.dld.2020.03.014↗
16. Sophie Deguelte · 2 shared papers, 2020–2021 · strength 0.21
    • Paper Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resecte… DOI 10.1186/s12893-021-01409-7↗
    • Paper Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic ade… DOI 10.1016/j.dld.2020.03.014↗
17. Gabriela Reyes‐Castellanos · 1 shared paper, 2022 · strength 0.19
    • Paper Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. DOI 10.1016/j.dld.2022.08.023↗
18. Alice Carrier · 1 shared paper, 2022 · strength 0.19
    • Paper Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. DOI 10.1016/j.dld.2022.08.023↗
19. Antoine Le Bozec · 1 shared paper, 2023 · strength 0.18
    • Paper Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective… DOI 10.3389/fphar.2023.1137791↗
20. Violette Fossaert · 1 shared paper, 2022 · strength 0.15
    • Paper Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival… DOI 10.3389/fonc.2022.980659↗
21. Patrick Pessaux · 1 shared paper, 2021 · strength 0.12
    • Paper Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resecte… DOI 10.1186/s12893-021-01409-7↗
22. Christelle d’Engremont · 1 shared paper, 2022 · strength 0.11
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
23. Frédéric Di Fiore · 1 shared paper, 2022 · strength 0.11
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
24. Lilian Schwarz · 1 shared paper, 2022 · strength 0.11
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗
25. Mehdi El Amrani · 1 shared paper, 2022 · strength 0.11
    • Paper Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French co… DOI 10.1016/j.ejca.2022.01.040↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.